{"disease":{"id":"familial-x-linked-hypophosphatemic-vitamin-d-refractory-rickets","name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"burosumab","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crysvita","generic_name":"BUROSUMAB","company_name":"Ultragenyx Pharm Inc","drug_phase":"marketed","molecular_target":"FGF23","drug_class":"","quality_score":62,"revenue":"700","mechanism":"Burosumab-twza binds to and inhibits FGF23, restoring renal phosphate reabsorption and increasing 1,25 dihydroxy vitamin D levels."},{"drug_id":"ergocalciferol","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drisdol","generic_name":"ERGOCALCIFEROL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","drug_class":"Provitamin D2 Compound [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"calciferol","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Calciferol","company_name":"Department of Medical Services Ministry of Public Health of Thailand","drug_phase":"phase_1","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"burosumab-twza","indication_name":"Familial x-linked hypophosphatemic vitamin D refractory rickets","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CRYSVITA","generic_name":"BUROSUMAB-TWZA","company_name":"KYOWA KIRIN","drug_phase":"marketed","molecular_target":"Fibroblast growth factor 23","drug_class":"","quality_score":20,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}